Histone deacetylase (HDAC) inhibitors represent promising therapeutic candidates for AMD, analogous to DNA hypomethylation-inducing agents, by modulating epigenetic pathways implicated in disease progression. This evidence concerns the gene HDAC9 and age-related macular degeneration.